[Treatment Targets in Hypertension]

Area of Science:

• Cardiology
• Hypertension Management
• Clinical Trials

Background:

• The optimal target blood pressure (BP) for treating hypertension is a subject of ongoing debate.
• The SPRINT trial indicated a systolic BP target of <120 mmHg offers prognostic advantages for high-risk elderly patients.
• This finding contrasts with other trials like SPS3, ACCORD, and HOPE-3, which explored intensive BP lowering.

Purpose of the Study:

• To evaluate the evidence surrounding target blood pressure goals in hypertensive patients.
• To analyze the discrepancies in outcomes between the SPRINT trial and other major BP intervention studies.
• To determine if a systolic BP target of <120 mmHg is definitively proven by conventional measurement methods.

Main Methods:

• Comparative analysis of intervention trials focusing on intensive blood pressure lowering.
• Examination of the blood pressure measurement procedures employed in key trials, particularly SPRINT.
• Review of existing literature and clinical evidence regarding hypertension treatment targets.

Main Results:

• The SPRINT trial's positive outcomes may be influenced by its "unobserved" blood pressure measurement technique.
• A target systolic blood pressure of <120 mmHg has not been conclusively demonstrated as beneficial using conventional BP measurement.
• Contradictory evidence from various trials highlights the complexity of establishing universal BP targets.

Conclusions:

• The optimal blood pressure target for hypertensive individuals requires further investigation.
• A universal systolic blood pressure goal of <120 mmHg is not yet substantiated by conventional measurement.
• Individualized treatment goals for hypertension management may be necessary given the current evidence.